Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novo Nordisk A/S ADR
(NY:
NVO
)
123.05
-0.97 (-0.78%)
Official Closing Price
Updated: 7:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Novo Nordisk A/S ADR
< Previous
1
2
3
4
5
6
7
8
9
...
43
44
Next >
Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says
April 12, 2024
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee found no conclusive evidence linking GLP-1 receptor agonists to suicidal or self-injurious thoughts. Following thorough...
Via
Benzinga
Exposures
Product Safety
Why Wall Street Got Even More Excited About The Glucose Monitor — And How Dexcom, Abbott Labs Stand To Benefit
April 12, 2024
Continuous glucose monitors have spiked in popularity since the advent of weight-loss drugs. Is chronic disease at its end?
Via
Investor's Business Daily
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024
April 12, 2024
We’re using the Portfolio Grader to find the best biotech stocks to buy in today’s market. Each of these stocks get top grades.
Via
InvestorPlace
Shed the Fat, Gain the Profits: 3 Weight-Loss Stocks to Own Until 2027
April 12, 2024
For investors looking for a way to play weight-loss stocks in this current backdrop, here are three top options to consider right now.
Via
InvestorPlace
What's Going On With Ginkgo Bioworks Stock?
April 11, 2024
Ginkgo Bioworks announced the expansion of its strategic partnership with Novo Nordisk A/S on Wednesday under a framework agreement that initially is contemplated to run over five years.Ginkgo said the...
Via
Benzinga
Check Out What Whales Are Doing With NVO
April 09, 2024
Via
Benzinga
Is NYSE:NVO a Good Fit for Dividend Investing?
April 09, 2024
Why NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) qualifies as a good dividend investing stock.
Via
Chartmill
Assessing Novo Nordisk: Insights From 10 Financial Analysts
April 05, 2024
Via
Benzinga
All-Time High Flyers: 7 Stocks to Buy as the Market Peaks
April 11, 2024
These stocks to buy have enjoyed big rallies and the gains look likely to continue in coming months even if the market does peak.
Via
InvestorPlace
3 Obesity Drug Stocks Set to Skyrocket as Demand Goes Wild
April 10, 2024
Discover top obesity drug stocks set to soar as demand surges. Eli Lilly, Novo Nordisk, & Dexcom lead with revolutionary treatments
Via
InvestorPlace
2 Healthcare Stocks to Buy Hand Over Fist in April
April 10, 2024
Don't wait too long to invest in these exciting stocks.
Via
The Motley Fool
Novo Nordisk's Stock Could Get Another Boost, Thanks to This Huge Development
April 10, 2024
It may not be too late to invest in this promising healthcare stock, even though it may look expensive.
Via
The Motley Fool
Viking Therapeutics Is Great. Here's Why You Shouldn't Buy It.
April 08, 2024
Shares of the clinical-stage biotech have skyrocketed on recent good news.
Via
The Motley Fool
Smart Money Is Betting Big In NVO Options
April 02, 2024
Via
Benzinga
Could This New Development Soon Buoy Eli Lilly and Novo Nordisk Stock?
April 07, 2024
New findings could lead to more growth from their prized medicines.
Via
The Motley Fool
The 7 Most Undervalued Russell 2000 Stocks to Buy in April 2024
April 05, 2024
With risk-on sentiment in place, investors may be looking for the most undervalued Russell 2000 stocks to buy in April.
Via
InvestorPlace
After Wegovy's Approval to Treat Heart Disease, Novo Nordisk Continues to Make Moves
April 04, 2024
Novo Nordisk is off to a red-hot start in 2024, and its latest deal could represent huge potential.
Via
The Motley Fool
Could This 1 Detail Help Viking Therapeutics Top Eli Lilly and Novo Nordisk in the Weight Loss Drug Market?
April 04, 2024
Viking shares have soared recently on optimism about its program.
Via
The Motley Fool
Why Eli Lilly Stock Topped the Market Today
April 03, 2024
One analyst following the company believes it could grow its revenue meaningfully this year.
Via
The Motley Fool
Eli Lilly Struggles To Keep Pace With Mounjaro, Zepbound Demand: 'Currently Unavailable' On Amazon Pharmacy
April 03, 2024
Eli Lilly's stock skyrockets but now trading sideways as demand for weight-loss drugs outpaces supply. Availability issues lead to FDA shortages.
Via
Benzinga
Exposures
Product Safety
Novo Nordisk's Popular Diabetes Drug Ozempic Starter Kits Face Extended Shortages in Germany, Faces Biosimilar Threat In China
April 03, 2024
Novo Nordisk warns of Ozempic starter kit scarcity in Germany amid ongoing supply challenges in Europe. Restrictions on off-label use emphasized, with intermittent shortages expected in 2024....
Via
Benzinga
Exposures
Product Safety
Hedge Fund Favorites: 3 European Stocks Attracting Significant U.S. Investment
April 03, 2024
Investors looking for diversification should consider these European names that are increasingly popular among hedge fund managers.
Via
InvestorPlace
Costco Long Known For Rotisserie Chicken And Hot Dogs Counters Junk Food With Weight Loss Plan To Help You Shed Those Extras
April 03, 2024
Costco's new weight loss initiative, in partnership with Sesame, a healthcare marketplace, will offer members a three-month clinical consultation and other services for $179.
Via
Benzinga
5 Healthcare Stocks to Buy for 2024
April 02, 2024
Healthcare stocks have been some of the top performers in 2024, and thanks to the potential of AI, these names will just keep heating up.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss Race
April 02, 2024
AstraZeneca's CEO Pascal Soriot celebrates hitting a $45 billion sales target set a decade ago despite initial skepticism. Investor confidence remains a challenge amid stagnant shares and concerns over...
Via
Benzinga
Citi Monitors Competitive Threats To Eli Lilly, Says It Is Positioned To Maintain Leadership And Expand
April 02, 2024
Citi Research raises price target for Eli Lilly, citing improved risk-adjusted sales outlook for GLP-1 agonist orforglipron. With Phase 3 trials ongoing since 2023, concerns about liver toxicity...
Via
Benzinga
Eli Lilly Stock Navigates Weight-Loss Drug Competition With Technical Resilience
April 02, 2024
Eli Lilly's stock has performed well over the past year, gaining 116.84%. So far in 2024, the stock has returned 29.45% to investors.
Via
Benzinga
Diabetes Drug Made For Under $5 Costs Americans $1,000, Drawing Comparisons To Martin Shrikeli While Juicing Profits for A Drug Giant
April 02, 2024
Via
Benzinga
Could Viking Therapeutics Stock Be a Millionaire Maker?
April 02, 2024
There is a plausible path for this biotech stock to make some investors millionaires.
Via
The Motley Fool
Is It Too Late to Buy Eli Lilly Stock?
April 02, 2024
There's more to the Lilly story than just excellence in one treatment area.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
43
44
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.